Table 4.
Changes in immunological parameters.
| Parameter | NVP-1703 | Placebo | |||
|---|---|---|---|---|---|
| 0 w | 4 w | 0 w | 4 w | p-Value † | |
| Blood eosinophil count (/μL) | 175.42 (16.21) | 96.82 (25.24) *** | 178.24 (17.14) | 56.61 (14.35) *** | 0.116 |
| D. pteronyssinus-specific IgE (KU/L) | 7.61 (1.14) | 7.15 (1.04) | 8.92 (1.18) | 8.93 (1.22) | 0.331 |
| D. farinae-specific IgE (KU/L) | 14.75 (2.17) | 12.83 (1.78) ** | 16.86 (2.20) | 17.19 (2.35) | 0.033 |
| IL-4 (log pg/mL) | 2.29 (0.12) | 2.31 (0.12) | 2.28 (0.12) | 2.28 (0.12) | 0.940 |
| IL-5 (log pg/mL) | 1.65 (0.12) | 1.59 (0.14) | 1.36 (0.12) | 1.34 (0.11) | 0.605 |
| IL-10 (log pg/mL) | 2.22 (0.11) | 2.16 (0.11) | 2.23 (0.09) | 1.97 (0.11)** | 0.047 |
| IL-13 (log pg/mL) | 1.49 (0.10) | 1.47 (0.12) | 1.55 (0.10) | 1.51 (0.10) | 0.936 |
| IFN-γ (log pg/mL) | 2.99 (0.08) | 2.98 (0.09) | 2.85 (0.08) | 2.84 (0.08) | 0.488 |
| IL-10/IL-4 | 1.21 (0.15) | 1.17 (0.16) | 1.42 (0.28) | 0.90 (0.09) | 0.046 |
| IL-10/IL-5 | 2.15 (0.24) | 2.27 (0.27) | 3.30 (0.47) | 2.27 (0.22) * | 0.088 |
| IL-10/IL-13 | 2.73 (0.42) | 2.77 (0.44) | 2.71 (0.41) | 1.95 (0.17) | 0.018 |
| IL-10/IFN-γ | 0.53 (0.05) | 0.52 (0.05) | 0.64 (0.08) | 0.49 (0.04) | 0.177 |
| Urinary LTE4 (ng/mmol Cr) | 601.06 (32.53) | 585.78 (31.24) | 546.95 (32.18) | 541.23 (32.31) | 0.701 |
| Urinary PGF2α (ng/mmol Cr) | 77.23 (7.66) | 69.90 (7.90) | 74.19 (6.82) | 72.13 (6.27) | 0.809 |
Data are expressed as mean (SEM). Cytokine levels were analyzed after logarithmic transformation. † p-value for change from baseline at 4 weeks between NVP-1703 and placebo groups. * p < 0.05, ** p < 0.01, *** p < 0.001 for change from baseline at 4 weeks within groups.